Cambrex to Invest 120 Million Dollars for Expanding U.S. Operations

Business Strategy Cambrex to Invest 120 Million Dollars for Expanding U.S. Operations

2025-10-24 Source: Press release Cambrex 2 min Reading Time

Related Vendors

Cambrex Corporation

Elementar Analysensysteme GmbH

Glatt Ingenieurtechnik GmbH

Italvacuum, Srl

With an aim to expand API manufacturing and strengthen its drug supply resilience in the USA, Cambrex has plans to invest a whopping amount of 120 million dollars in the country.

The 120-million-dollar investment will support a 40 % increase in the Charles City, Iowa site's large-scale manufacturing capacity, reaching nearly one million liters.(Source: Pixabay) — The 120-million-dollar investment will support a 40 % increase in the Charles City, Iowa site's large-scale manufacturing capacity, reaching nearly one million liters.
(Source: Pixabay)

New Jersey/USA – Cambrex recently announced a 120-million-dollar investment to expand its U.S. operations, addressing increased demand for API development and manufacturing, and accelerating the company's leadership role in the fast-growing peptide therapeutics market.

"Our customers, in partnership with federal and state agencies, are reshoring drug manufacturing in the U.S., the world's largest pharmaceutical market. Local API production is vital for supply chain security and resilience, and Cambrex will play a key role. We are seeing very strong demand from our customers to partner with Cambrex to utilize this expanded capacity," commented Thomas Loewald, CEO of Cambrex.

The 120-million-dollar investment will support a 40 % increase in the Charles City, Iowa site's large-scale manufacturing capacity, reaching nearly one million liters. The Charles City facility, situated on a 45-acre site, manufactures a broad range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.

Stay up to Date

Do you want the latest news, specialist articles and information on new products? Then you can register for our free newsletter:

Choose your Newsletter

"With rising demand for U.S.-based supply chains for critical therapies, Cambrex is focused on supporting the long-term stability of pharmaceutical manufacturing in the United States," Loewald added. "The investment in our Charles City facility, the nation's largest independent API manufacturing site, reflects our commitment to meeting clients' evolving needs for small molecule and peptide manufacturing."

Today's commitment builds on Cambrex's heritage of investing in its drug development and manufacturing network, and follows previous expansions over the past five years, including:

The addition of highly potent API and large-scale manufacturing capacity in Charles City, Iowa. (2022)

New, state-of-the-art laboratories, clinical and small-to-medium volume commercial manufacturing capacity, designed for commercial therapies targeting rare diseases and orphan designations, in High Point, North Carolina. (2023)

Expanded capabilities and new GMP manufacturing capacity for peptide therapeutics in Waltham, Massachusetts. (2025)

(ID:50602644)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.